Psoriasis - severe chronic plaque psoriasis - adult patients

The Pharmaceutical Benefits Scheme (PBS) subsidises biological agents for adult patients with severe chronic plaque psoriasis.

Patient eligibility

The PBS subsidises treatment with biological agents under the National Health Act 1953, sections 85 and 100 for adult patients with severe chronic plaque psoriasis.

Where the term biological agent appears, it refers to:

  • adalimumab
  • etanercept
  • guselkumab
  • infliximab
  • ixekizumab
  • secukinumab
  • tildrakizumab
  • ustekinumab.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing biological agents.

Section 100 arrangements

Infliximab is only available for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

Infliximab isn’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Toxicity criteria and severity descriptors

When demonstrating a patient’s intolerance to prior treatment, use the severe chronic plaque psoriasis toxicity and severity descriptors with the authority application.

Treatment specifics

To be eligible for PBS subsidised treatment with these biological agents, patients must be treated by a dermatologist with expertise in the management of severe chronic plaque psoriasis

Applications

Initial treatment

Apply for initial authority approval to prescribe PBS subsidised biological agents to treat severe chronic plaque psoriasis in writing and either:

All applications must include the completed:

Initial grandfather treatment

For patients who received non-PBS subsidised guselkumab or tildrakizumab before 1 February 2019 for severe chronic plaque psoriasis, apply for all initial grandfather authority approval in writing and either:

All applications must include the completed:

Changing or recommencing treatment

Apply for authority approval to change or recommence PBS subsidised biological agents to treat severe chronic plaque psoriasis in writing and either:

All applications must include the completed:

You can use this authority application form to submit a demonstration of response to the current PBS subsidised treatment.

Continuing treatment

Apply for authority approval to continue PBS subsidised biological agents to treat severe chronic plaque psoriasis in writing and either:

All applications must include the completed:

After we approve the first application for continuing treatment with infliximab, subsequent continuing applications for biosimilar brands are:

  • S100 - HSD (Public) - Authority Required (Streamlined) and don’t need authority approval from us for the listed quantity and repeats
  • S100 - HSD (Private) - Authority Required (Telephone) - you can call the PBS Complex Drugs Programs enquiry line to request authority approval.

After we approve the first application for continuing treatment with etanercept, subsequent continuing applications for biosimilar brands are Authority Required (Streamlined). You don’t need prior authority approval from us for the listed quantity and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 May 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.